Pall signs supply agreement with Kaneka

Published: 19-Jan-2016

Will sell and provide technical support for KanCapA Protein A chromatography sorbent

Pall Corporation, a filtration, separation and purification specialist, has agreed to supply KANEKA KanCapA resin for the industrial-scale purification of monoclonal antibodies.

KanCapA, from Japanese firm KANEKA, is based on a unique combination of a proprietary recombinant alkaline stable Protein A and an innovative highly cross-linked cellulose base matrix. It enables the high productivity affinity capture of monoclonal antibodies and related biomolecules using a proprietary alkali stable rPrA ligand.

Pall will supply the product in a range of pre-packed columns and high throughput screening tools, as well as in bulk for use in the Resolute AutoPak columns.

Key features of KANEKA KanCapA, which is manufactured in a state-of-the art facility in Japan, are its high dynamic binding capacity, good flow performance and optimal alkali stability for reuse, which are key attributes for both batch and continuous chromatography, Pall said.


KANEKA KanCapA provides the key chromatographic step required in a typical MAb purification process

The introduction of KANEKA KanCapA expands Pall's portfolio of continuous bioprocessing and chromatography products. It also complements Pall's recent acquisition of the BioSMB multicolumn continuous chromatography platform from Tarpon Biosystems, and the licensing of the Acoustic Wave Separation (AWS) technology from FloDesign Sonics.

Michael Egholm, Vice President and General Manager of Pall Biopharmaceuticals said KANEKA KanCapA provides 'the key chromatographic step required in a typical MAb purification process' and integrates with the firm's cation exchange sorbents and Mustang Q membrane chromatography.

'Our customers will be able to go directly from CHO cell culture in the bioreactor to continuous clarification using AWS and STAX depth filtration products to provide a continuous feed stream for direct integration with the BioSMB platform,' he said.

Pall plans to introduce a single-use product line including AWS and BioSMB technologies for the purification of biological material from cell culture at both bench and GMP scale to match pilot and production bioreactor volumes, with predictable and reproducible performance over a wide range of cell densities.

You may also like